Research Analysts Set Expectations for HRTX Q1 Earnings

Key Points

• HC Wainwright lowered its Q1 2026 EPS estimate for Heron to ($0.04) from ($0.03) while maintaining a "Buy" rating and $6.00 price target; the firm also projects Q3 2026 EPS of ($0.02) and FY2026 EPS of ($0.08), versus a consensus FY loss of ($0.05).
• Heron beat expectations in its most recent quarter, reporting ($0.02) EPS vs. a ($0.03) consensus loss and $40.6M revenue vs. $39.5M estimates, but the stock trades near $1.19 with a market cap of about $224M and a 52‑week range of $0.74–$2.61.
• Analyst sentiment is mixed—three Buys, one Hold and one Sell yield an average "Hold" rating and $4.50 target—and institutional investors now own roughly 80% of the company following several large stake increases.

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - HC Wainwright dropped their Q1 2026 earnings estimates for shares of Heron Therapeutics in a report released on Thursday, April 23rd. HC Wainwright analyst B. Folkes now expects that the biotechnology company will post earnings per share of ($0.04) for the quarter, down from their prior estimate of ($0.03). HC Wainwright has a "Buy" rating and a $6.00 price target on the stock. The consensus estimate for Heron Therapeutics' current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for Heron Therapeutics' Q3 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.08) EPS.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The firm had revenue of $40.59 million during the quarter, compared to analyst estimates of $39.53 million.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reissued a "sell (e+)" rating on shares of Heron Therapeutics in a research note on Tuesday, April 21st. Zacks Research raised shares of Heron Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Friday, March 27th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $4.50.

Heron Therapeutics Stock Performance

Heron Therapeutics stock opened at $1.19 on Monday. The company has a 50 day moving average price of $0.96 and a 200 day moving average price of $1.16. Heron Therapeutics has a 52 week low of $0.74 and a 52 week high of $2.61. The company has a debt-to-equity ratio of 10.59, a quick ratio of 1.51 and a current ratio of 2.48. The firm has a market capitalization of $224.48 million, a price-to-earnings ratio of -9.15 and a beta of 1.42.

Institutional Investors Weigh In On Heron Therapeutics

Institutional investors have recently modified their holdings of the stock. Baker BROS. Advisors LP acquired a new stake in shares of Heron Therapeutics during the 3rd quarter valued at $5,357,000. Citigroup Inc. lifted its stake in shares of Heron Therapeutics by 4,666.9% in the 3rd quarter. Citigroup Inc. now owns 2,476,529 shares of the biotechnology company's stock valued at $3,120,000 after purchasing an additional 2,424,576 shares during the last quarter. JW Asset Management LLC lifted its stake in shares of Heron Therapeutics by 40.8% in the 3rd quarter. JW Asset Management LLC now owns 3,292,633 shares of the biotechnology company's stock valued at $4,149,000 after purchasing an additional 954,890 shares during the last quarter. New York State Common Retirement Fund lifted its stake in shares of Heron Therapeutics by 46.4% in the 3rd quarter. New York State Common Retirement Fund now owns 2,576,716 shares of the biotechnology company's stock valued at $3,247,000 after purchasing an additional 816,671 shares during the last quarter. Finally, Clearline Capital LP lifted its stake in shares of Heron Therapeutics by 1,033.1% in the 3rd quarter. Clearline Capital LP now owns 9,712,527 shares of the biotechnology company's stock valued at $12,238,000 after purchasing an additional 8,855,361 shares during the last quarter. Institutional investors and hedge funds own 80.01% of the company's stock.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company's research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron's first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.